The biotech market is buzzing with big-ticket buyouts of companies focused on cell therapies. Why? Consider that the CAR-T cell therapy market alone is expected to grow by 45.6% by 2025. And the CAR-T revolution is just the beginning of a new era in which scientists and emerging biotech companies are developing “living drugs” to treat all types of diseases.
This event will bring esteemed executives from emerging cell therapy companies together to discuss where the industry is headed and how their companies, individually and collectively, may lead us into the new era. Our moderator will translate this insider foresight into investment insight, helping you evaluate cell therapy companies to capitalize on their success.